Drugs / 851B
851B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00117884 | Apr 2006 → Jun 2008 | anogenital human papillomavirus infection | Takeda | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00312286 Comparator | Apr 2006 → Jun 2008 | human papilloma virus infection | Takeda | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 851B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00312286 ↗ |
| Known as | EPETIRIMOD ESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103807 ↗ |
| Known as | Epetirimod esylate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103807 ↗ |
| Known as | S-30563-35-65 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103807 ↗ |
| Modality | Small molecule | — CHEMBL2103807 ↗ |
| Route | Topical | “topically” NCT00117884 ↗ |